InterMune, Inc. (NASDAQ:ITMN)
| CAPS Rating |
|
|---|---|
| Open | $15.15 |
| Previous Close | $15.41 |
| Daily Range | $14.38 - $15.50 |
| 52-Week Range | $10.67 - $51.71 |
| Market Cap | $881.09M |
| P/E Ratio | 11.70 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 1,963,354 |
| Average Daily Volume | 0 |
ITMN
VS S&P 500 (SPY)
How do you think ITMN will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ITMN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ITMN News and Commentary
- InterMune Widens Loss, Sales Dip - Analyst Blog – NASDAQ
- 3 Lessons From the J.P. Morgan Health-Care Confab – The Motley Fool
- The 2 Biotechs Ramping Up Sales – The Motley Fool
- InterMune 4Q Esbriet Sales Snapshot - Analyst Blog – NASDAQ
- The Week's Top Stock Gainers – The Motley Fool
- Tomorrow's Monster Stock – The Motley Fool
- Are These Biotech Drug Launches Back on Track? – The Motley Fool
- InterMune Shares Popped: What You Need to Know – The Motley Fool
- 3 Stock-Moving Binary Events to Watch in 2012 – The Motley Fool
- The Worst Health Care Stocks of 2011 – The Motley Fool
- 5 of Last Week's Biggest Losers – The Motley Fool
- A Fool Looks Back – The Motley Fool
- Safety (Still) Trumps Acquisitions in Hep C – The Motley Fool
- InterMune Shares Plunged: What You Need to Know – The Motley Fool
- 1 Massive Biotech Bloodbath – The Motley Fool
- InterMune's Shares Got Crushed: What You Need to Know – The Motley Fool
- A Soaring Biotech With Room to Run – The Motley Fool
- Don't Get Too Worked Up Over InterMune's Earnings – The Motley Fool
- The Zacks Analyst Blog Highlights: Gilead Sciences, Pharmasset, Nasdaq Biotechnology ETF, InterMune – NASDAQ
- 3 Health Care Stocks That Could Gain 50% or More – NASDAQ
RSS Headlines
Fool UK
